Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228

✍ Scribed by Grégoire P. Prevost; Anne Pradines; Marie-Christine Brezak; Marie-Odile Lonchampt; Isabelle Viossat; Isabelle Ader; Christine Toulas; Philip Kasprzyk; Thomas Gordon; Gilles Favre; Barry Morgan

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: French
• Weight: 100 KB
• Volume: 91
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1104>3.0.co;2-s

✦ Synopsis

Oncogenic mutations of the ras gene leading to constitutive activation of downstream effectors have been detected in a wide spectrum of human cancers (pancreas, thyroid, colon, non-small-cell lung cancer). Membrane anchorage of Ras, required for functional activity in signal transduction, is facilitated by post-translational modifications resulting in covalent attachment of a farnesyl group to the cysteine in the C-terminal CAAX motif. This attachment is mediated by farnesyltransferase (FTase). Here, we report a novel FTase inhibitor, BIM-46228, which showed (i) specific inhibition of purified human FTase enzyme, (ii) inhibition of proliferation in vitro in a large spectrum of human tumor cell lines, (iii) inhibition of growth of human tumor xenografts in athymic nude mice treated by per os administration and (iv) the benefits of in vitro combination of its activity with chemotherapy or radiotherapy.